|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Nifedipine#Use in Specific Populations]] |
| {{Nifedipine}}
| |
| {{CMG}}; {{AE}}: {{AK}}
| |
| | |
| '''''For patient information about Nifedipine, click [[Nifedipine (patient information)|here]].'''''
| |
| | |
| ==Use in Specific Populaion==
| |
| | |
| ===Pregnancy:===
| |
| | |
| '''Pregnancy Category C:'''
| |
| | |
| Nifedipine has been shown to produce teratogenic findings in rats and rabbits, including digital anomalies similar to those reported for phenytoin. Digital anomalies have been reported to occur with other members of the [[dihydropyridine]] class and are possibly a result of compromised uterine blood flow. Nifedipine administration was associated with a variety of embryotoxic, placentotoxic, and fetotoxic effects, including stunted fetuses (rats, mice, rabbits), rib deformities (mice), cleft palate (mice), small placentas and underdeveloped [[chorionic villi]] (monkeys), embryonic and fetal deaths (rats, mice, rabbits), and prolonged pregnancy/decreased neonatal survival (rats; not evaluated in other species). On a mg/kg basis, all of the doses associated with the teratogenic embryotoxic or fetotoxic effects in animals were higher (5 to 50 times) than the maximum recommended human dose of 120 mg/day. On a mg/m2 basis, some doses were higher and some were lower than the maximum recommended human dose but all were within an order of magnitude of it. The doses associated with placentotoxic effects in monkeys were equivalent to or lower than the maximum recommended human dose on a mg/m2 basis.
| |
| | |
| There are no adequate and well-controlled studies in pregnant women. Nifedipine should be used during pregnancy only if the potential benefit justifies the potential risk.
| |
| | |
| ===Lactation: ===
| |
| | |
| Nifedipine is transferred through breast milk. Nifedipine should be used during breastfeeding only if the potential benefit justifies the potential risk.
| |
| | |
| ===Pediatric Use:===
| |
| | |
| Safety and effectiveness in pediatric patients have not been established. Use in pediatric population is not recommended.
| |
| | |
| ===Geriatric Use:===
| |
| | |
| Age appears to have a significant effect on the pharmacokinetics of nifedipine. The clearance is decreased resulting in a higher AUC in the elderly. These changes are not due to changes in renal function (see [[nifedipine clinical pharmacology|CLINICAL PHARMACOLOGY, Pharmacokinetics]]).
| |
| | |
| | |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03be089c-07e5-4f94-bfcc-c6101b311785
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |